Lutetium (177Lu) chloride Billev (previously Illuzyce) (lutetium (177Lu) chloride)
- Region
- 🇪🇺 EU
- Active substance
- lutetium (177Lu) chloride
- Company
- Billev Pharma Aps
- Status
- Authorised
- Therapeutic area
- Radionuclide Imaging
- CHMP opinion
- Thu 21 Jul 2022
- EU approval
- Thu 15 Sep 2022
- Application
- EMEA/H/C/005859
- ATC
- V10X
- Official record
- www.ema.europa.eu
Indication
Lutetium (177Lu) chloride Billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177Lu) chloride.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Theralugand Authorised · Eckert & Ziegler Radiopharma GmbH
- 🇪🇺 EndolucinBeta Authorised · ITM Medical Isotopes GmbH
- 🇪🇺 Ilumira Authorised · Shine Europe B.V.
- 🇪🇺 Lumark Withdrawn · I.D.B. Radiopharmacy B.V.
Follow Lutetium (177Lu) chloride Billev (previously Illuzyce)
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.